Hyperfine (HYPR) vs TriSalus Life Sciences (TLSI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
TriSalus Life Sciences (TLSI) has outperformed Hyperfine (HYPR) over the past year, losing 14.8% versus a loss of 55.0%. Over five years, TLSI leads with a -58.3% price change compared with -90.5% for HYPR. TriSalus Life Sciences is the larger company by market cap ($250.0 million vs $98.7 million), about 2.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HYPR | TLSI |
|---|---|---|
| Share price | $0.9307 | $4.06 |
| Market cap | $98.70M | $249.99M |
| 1-day change | -1.00% | -1.69% |
| YTD return | -3.97% | -40.83% |
| 1-year return | -55.02% | -14.85% |
| 5-year return | -90.54% | -58.28% |
| EPS (TTM) | $-0.37 | $-1.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.22 | $7.95 |
| 52-week low | $0.754 | $2.20 |
| Distance from 52-week high | -58.08% | -48.93% |
| Analyst consensus | none | none |
| Avg. price target upside | +118.12% | +156.16% |
| Average volume | 765.15K | 275.38K |
| Shares outstanding | 90.99M | 61.57M |
| Employees | 102 | 102 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TriSalus Life Sciences is about 2.5 times larger than Hyperfine by market value ($249.99M vs $98.70M).
- TLSI has outperformed HYPR by 40.2 percentage points over the past year.
About Hyperfine
HYPR stock →Hyperfine, Inc., a health technology company, engages in the production, supply, service, and commercialization of magnetic resonance imaging (MRI) products. Its Swoop Portable MR Imaging System produces images at a lower magnetic field strength than conventional MRI scanners.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 102 employees
About TriSalus Life Sciences
TLSI stock →TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States.
Health Care · Medical Specialities · 102 employees
HYPR vs TLSI FAQ
Which is bigger, Hyperfine or TriSalus Life Sciences?
TriSalus Life Sciences (TLSI) is larger, with a market capitalization of $249.99M compared with $98.70M for Hyperfine (HYPR).
Which stock has performed better over the past year, HYPR or TLSI?
TLSI returned -14.85% over the past 12 months, compared with -55.02% for HYPR (price return, excluding dividends). Past performance does not predict future results.
Are Hyperfine and TriSalus Life Sciences in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Electromedical & Electrotherapeutic Apparatus for Hyperfine and Medical Specialities for TriSalus Life Sciences.